Samsara BioCapital’s Novavax NVAX Stock Holding History

Samsara BioCapital’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,244	Closed	-$158K	–	44
2023 Q2	$158K	Hold	21,244	–	–	0.03%	44
2023 Q1	$147K	Hold	21,244	–	–	0.03%	52
2022 Q4	$218K	Hold	21,244	–	–	0.05%	50
2022 Q3	$387K	Hold	21,244	–	–	0.09%	50
2022 Q2	$1.09M	Sell	21,244 -5,900	-22%	-$306K	0.29%	44
2022 Q1	$2M	Hold	27,144	–	–	0.5%	40
2021 Q4	$3.88M	Sell	27,144 -3,016	-10%	-$518K	0.75%	26
2021 Q3	$6.25M	Hold	30,160	–	–	0.98%	24
2021 Q2	$6.4M	Hold	30,160	–	–	0.79%	24
2021 Q1	$5.47M	Hold	30,160	–	–	1.01%	23
2020 Q4	$3.36K	Buy	30,160 +8,500	+39%	+$903K	0.34%	28
2020 Q3	$2.35M	Buy	+21,660	New	+$2.64M	0.65%	25

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Samsara BioCapital's NVAX Position: Q3 2023 in Review

Samsara BioCapital sold out of Novavax (NVAX) in Q3 2023, closing a stake of 21,244 shares — an estimated $158K sold.

Samsara BioCapital first reported a position in NVAX in Q3 2020 and held it in 12 quarters. The position peaked at $6.4M in Q2 2021. 225 funds tracked by Wall St. Rank hold NVAX as of Q3 2023.

Samsara BioCapital reported no remaining Novavax position as of Q3 2023 after selling out during the quarter.
Samsara BioCapital sold 21,244 Novavax shares in Q3 2023, an estimated $158K.
Samsara BioCapital first reported a position in Novavax in Q3 2020 and held it in 12 quarters.
Samsara BioCapital's Novavax position peaked at $6.4M in Q2 2021.
225 funds tracked by Wall St. Rank held Novavax as of Q3 2023.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.